ISRCTN39498786 https://doi.org/10.1186/ISRCTN39498786

A comparison of hybrid chemotherapy versus hybrid chemotherapy and autotransplant in poor prognosis Hodgkin's disease

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 13/06/2014	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
SNLG HDIII

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Lymphoma (Hodgkin's)

Interventions
All patients receive three 28-day cycles of PVACE-BOP (chlorambucil, procarbazine, etoposide, vinblastine, adriamycin, bleomycin and prednisolone), together with co-trimoxazole every 3 weeks for the duration of treatment.

Patients who achieve at least a partial remission are randomised to one of two treatment regimens:
1. Regimen A: Radiotherapy, 30 Gy in 3 weeks to initially bulky sites or residual areas of disease, followed by two further cycles of PVACE-BOP
2. Regimen B: Radiotherapy, 30 Gy in 3 weeks to initially bulky sites or residual areas of disease, followed by intensive chemotherapy with melphan and etoposide plus autologous bone marrow transplantation.

Intervention Type
Other

Phase
Not Applicable

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s)
Not provided at time of registration

Completion date
31/12/2004

Eligibility

Key inclusion criteria
1. Histological diagnosis of Hodgkin's disease
2. Prognostic index of at least 0.5
3. Aged under 60
4. No prior chemotherapy or radiotherapy
5. No known significant heart, lung or renal disease
6. No co-existing malignancies apart from localised skin lesions

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2001

Date of final enrolment
31/12/2004

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

UK Co-ordinating Committee for Cancer Research (UKCCCR)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Not defined

Funder Name
Not provided at time of registration

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2002		Yes	No